A Novel Rapid Step Test Differentiates Between Older Adults Who are Fallers and Non-Fallers

Each year one in three adults \u3e 65 years old falls which results in significant morbidity, mortality and health care costs. Commonly used balance tests such as the Balance Evaluation Systems Test, Berg Balance Scale and Tinetti produce numerical results that have been correlated with a fall history. However, these tests can be complicated, time consuming, require a large amount of space, may require special tools for assessment and exhibit a ceiling effect. Additionally, dynamic balance recovery strategies such as rapid stepping movements may not be fully assessed by some of these other traditional tests.https://ecommons.udayton.edu/dpt_symposium/1017/thumbnail.jp

Planning for tranquil spaces in rural destinations through mixed methods research

There is a view that applied researchers produce more relevant findings for practitioners in the tourism industry if they use quantitative methods. This paper claims that findings relevant to industry can be produced through the use of qualitative methods of data collection, and indeed a unique perspective is offered by qualitative research that a quantitative approach may not produce. Furthermore, a mixed methods approach to research combines the advantages offered by both qualitative and quantitative research, and is advocated as an appropriate way forward when both types of data are needed. Using a unique mixed-methods study of the meaning of tranquillity to visitors to and authorities and residents in Dorset, Southern England, this paper illustrates the value of both qualitative and quantitative data to tourism planners. The study reveals that tranquillity was most commonly aligned to the natural environment whereas non-tranquillity concerned both sounds and sights of manmade origin

A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment

This paper is a personal account on the discovery and characterization of the 5-HT2C receptor (first known as the 5- HT1C receptor) over 30 years ago and how it translated into a number of unsuspected features for a G protein-coupled receptor (GPCR) and a diversity of clinical applications. The 5-HT2C receptor is one of the most intriguing members of the GPCR superfamily. Initially referred to as 5-HT1CR, the 5-HT2CR was discovered while studying the pharmacological features and the distribution of [3H]mesulergine-labelled sites, primarily in the brain using radioligand binding and slice autoradiography. Mesulergine (SDZ CU-085), was, at the time, best defined as a ligand with serotonergic and dopaminergic properties. Autoradiographic studies showed remarkably strong [3H]mesulergine-labelling to the rat choroid plexus. [3H]mesulergine-labelled sites had pharmacological properties different from, at the time, known or purported 5-HT receptors. In spite of similarities with 5-HT2 binding, the new binding site was called 5-HT1C because of its very high affinity for 5-HT itself. Within the following 10 years, the 5-HT1CR (later named 5- HT2C) was extensively characterised pharmacologically, anatomically and functionally: it was one of the first 5-HT receptors to be sequenced and cloned. The 5-HT2CR is a GPCR, with a very complex gene structure. It constitutes a rarity in theGPCR family: many 5-HT2CR variants exist, especially in humans, due to RNA editing, in addition to a few 5-HT2CR splice variants. Intense research led to therapeutically active 5-HT2C receptor ligands, both antagonists (or inverse agonists) and agonists: keeping in mind that a number of antidepressants and antipsychotics are 5- HT2CR antagonists/inverse agonists. Agomelatine, a 5-HT2CR antagonist is registered for the treatment of major depression. The agonist Lorcaserin is registered for the treatment of aspects of obesity and has further potential in addiction, especially nicotine/ smoking. There is good evidence that the 5-HT2CR is involved in spinal cord injury-induced spasms of the lower limbs, which can be treated with 5-HT2CR antagonists/inverse agonists such as cyproheptadine or SB206553. The 5-HT2CR may play a role in schizophrenia and epilepsy. Vabicaserin, a 5-HT2CR agonist has been in development for the treatment of schizophrenia and obesity, but was stopped. As is common, there is potential for further indications for 5-HT2CR ligands, as suggested by a number of preclinical and/or genome-wide association studies (GWAS) on depression, suicide, sexual dysfunction, addictions and obesity. The 5-HT2CR is clearly affected by a number of established antidepressants/antipsychotics and may be one of the culprits in antipsychotic-induced weight gain